

2019 Regular Session

HOUSE RESOLUTION NO. 257

BY REPRESENTATIVE HOFFMANN

A RESOLUTION

To urge and request the Louisiana Department of Health to make changes necessary to eliminate prior authorization requirements while controlling costs in the Medicaid program for buprenorphine/naloxone and naltrexone for opioid use disorder treatment.

WHEREAS, medication treatments for opioid use disorder are effective and are the current standard of care; and

WHEREAS, unnecessary prior authorizations create a barrier for patient access to medication treatments and increase administrative complexity for providers; and

WHEREAS, the amount that the state pays for medication treatments should reflect the value that medication treatments bring through improved clinical outcomes among Medicaid members.

THEREFORE, BE IT RESOLVED that the House of Representatives of the Legislature of Louisiana does hereby urge and request the Louisiana Department of Health to make changes necessary to eliminate prior authorization requirements in the Medicaid program for all formulations of buprenorphine/naloxone and naltrexone.

BE IT FURTHER RESOLVED that the department should pursue value-based payment arrangements, as have been successful in other state Medicaid programs, to increase access to buprenorphine/naloxone and naltrexone products in a cost-effective manner that ensures that Medicaid members benefit from state expenditures for these drugs.

BE IT FURTHER RESOLVED that the department should ensure that quantity limits placed on medications to treat opioid use disorder are aligned with the American Society of Addiction Medicine (ASAM) National Practice Guideline for the Use of Medications in the Treatment of Addiction Involving Opioid Use.

BE IT FURTHER RESOLVED that a copy of this Resolution be transmitted to the secretary of the Louisiana Department of Health.

---

SPEAKER OF THE HOUSE OF REPRESENTATIVES